Kopran（524280）株式概要総合製薬会社であるコプラン・リミテッドは、インド国内外で医薬品原薬と完成品の製造・販売を行っている。 詳細524280 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績1/6財務の健全性5/6配当金3/6リスク分析過去5年間で収益は年間14.7%減少しました。 1.56%の配当はフリーキャッシュフローで十分にカバーされていない Indian市場と比較した過去 3 か月間の株価の変動意味のある時価総額がありません ( ₹9B )+1 さらなるリスクすべてのリスクチェックを見る524280 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW498,716 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG498,716 investors already sharing narrativesYour Fair Value₹Current Price₹192.9024.8% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture010b2016201920222025202620282031Revenue ₹9.7bEarnings ₹367.2mAdvancedSet Fair ValueView all narrativesKopran Limited 競合他社WanburySymbol: BSE:524212Market cap: ₹9.9bShree Ganesh RemediesSymbol: BSE:540737Market cap: ₹8.4bVikram Thermo (India)Symbol: BSE:530477Market cap: ₹7.5bAnuh PharmaSymbol: BSE:506260Market cap: ₹8.1b価格と性能株価の高値、安値、推移の概要Kopran過去の株価現在の株価₹192.9052週高値₹218.9052週安値₹107.00ベータ0.861ヶ月の変化0.55%3ヶ月変化43.37%1年変化6.69%3年間の変化9.23%5年間の変化-17.95%IPOからの変化136.54%最新ニュースNew Risk • May 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (9.3% average weekly change). Profit margins are more than 30% lower than last year (3.8% net profit margin). Market cap is less than US$100m (₹9.11b market cap, or US$95.6m).New Risk • May 21New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.8% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (3.8% net profit margin). Market cap is less than US$100m (₹8.07b market cap, or US$83.9m).Reported Earnings • May 21Full year 2026 earnings released: EPS: ₹5.33 (vs ₹7.98 in FY 2025)Full year 2026 results: EPS: ₹5.33 (down from ₹7.98 in FY 2025). Revenue: ₹6.82b (up 8.3% from FY 2025). Net income: ₹257.3m (down 33% from FY 2025). Profit margin: 3.8% (down from 6.1% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • May 19Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹172, the stock trades at a trailing P/E ratio of 50.3x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 22% over the past three years.お知らせ • May 06Kopran Limited to Report Q4, 2026 Results on May 19, 2026Kopran Limited announced that they will report Q4, 2026 results on May 19, 2026Buy Or Sell Opportunity • Apr 08Now 21% overvaluedOver the last 90 days, the stock has fallen 3.8% to ₹146. The fair value is estimated to be ₹121, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.8% over the last 3 years. Earnings per share has declined by 5.0%.最新情報をもっと見るRecent updatesNew Risk • May 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (9.3% average weekly change). Profit margins are more than 30% lower than last year (3.8% net profit margin). Market cap is less than US$100m (₹9.11b market cap, or US$95.6m).New Risk • May 21New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.8% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (3.8% net profit margin). Market cap is less than US$100m (₹8.07b market cap, or US$83.9m).Reported Earnings • May 21Full year 2026 earnings released: EPS: ₹5.33 (vs ₹7.98 in FY 2025)Full year 2026 results: EPS: ₹5.33 (down from ₹7.98 in FY 2025). Revenue: ₹6.82b (up 8.3% from FY 2025). Net income: ₹257.3m (down 33% from FY 2025). Profit margin: 3.8% (down from 6.1% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • May 19Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹172, the stock trades at a trailing P/E ratio of 50.3x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 22% over the past three years.お知らせ • May 06Kopran Limited to Report Q4, 2026 Results on May 19, 2026Kopran Limited announced that they will report Q4, 2026 results on May 19, 2026Buy Or Sell Opportunity • Apr 08Now 21% overvaluedOver the last 90 days, the stock has fallen 3.8% to ₹146. The fair value is estimated to be ₹121, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.8% over the last 3 years. Earnings per share has declined by 5.0%.Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹125, the stock trades at a trailing P/E ratio of 36.6x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 3.8% over the past three years.Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹142, the stock trades at a trailing P/E ratio of 41.4x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 16% over the past three years.Buy Or Sell Opportunity • Feb 04Now 22% overvaluedOver the last 90 days, the stock has fallen 14% to ₹138. The fair value is estimated to be ₹113, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.8% over the last 3 years. Earnings per share has declined by 5.0%.New Risk • Feb 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Profit margins are more than 30% lower than last year (2.7% net profit margin). Market cap is less than US$100m (₹6.48b market cap, or US$71.8m).Reported Earnings • Jan 24Third quarter 2026 earnings released: EPS: ₹1.93 (vs ₹2.16 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.93 (down from ₹2.16 in 3Q 2025). Revenue: ₹1.94b (up 17% from 3Q 2025). Net income: ₹93.4m (down 10% from 3Q 2025). Profit margin: 4.8% (down from 6.3% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 1% per year.お知らせ • Jan 13Kopran Limited to Report Q3, 2026 Results on Jan 22, 2026Kopran Limited announced that they will report Q3, 2026 results on Jan 22, 2026Valuation Update With 7 Day Price Move • Dec 23Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹153, the stock trades at a trailing P/E ratio of 42x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 3.0% over the past three years.Reported Earnings • Nov 17Second quarter 2026 earnings released: ₹2.06 loss per share (vs ₹1.53 profit in 2Q 2025)Second quarter 2026 results: ₹2.06 loss per share (down from ₹1.53 profit in 2Q 2025). Revenue: ₹1.18b (down 22% from 2Q 2025). Net loss: ₹99.2m (down 234% from profit in 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has increased by 1% per year.お知らせ • Oct 31Kopran Limited to Report Q2, 2026 Results on Nov 12, 2025Kopran Limited announced that they will report Q2, 2026 results on Nov 12, 2025お知らせ • Sep 11Kopran Limited Appoints Chandresh Gunvant Gandhi as Independent DirectorKopran Limited at its Sixty-sixth Annual General Meeting held on September 11, 2025, approved the appointment of Mr. Chandresh Gunvant Gandhi (DIN: 00707947) as an Independent Director.Valuation Update With 7 Day Price Move • Sep 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹185, the stock trades at a trailing P/E ratio of 25.5x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 8.8% over the past three years.Upcoming Dividend • Aug 28Upcoming dividend of ₹3.00 per shareEligible shareholders must have bought the stock before 04 September 2025. Payment date: 11 October 2025. Payout ratio is a comfortable 38% but the company is not cash flow positive. Trailing yield: 1.9%. Within top quartile of Indian dividend payers (1.3%). Higher than average of industry peers (0.8%).Declared Dividend • Aug 13Dividend of ₹3.00 announcedDividend of ₹3.00 is the same as last year. Ex-date: 4th September 2025 Payment date: 11th October 2025 Dividend yield will be 1.9%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (38% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has not increased over the past 5 years but payments have been stable during that time. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend.New Risk • Jul 30New major risk - Revenue and earnings growthEarnings have declined by 3.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.7% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (5.6% net profit margin). Market cap is less than US$100m (₹8.13b market cap, or US$93.1m).Reported Earnings • Jul 30First quarter 2026 earnings released: EPS: ₹1.54 (vs ₹2.30 in 1Q 2025)First quarter 2026 results: EPS: ₹1.54 (down from ₹2.30 in 1Q 2025). Revenue: ₹1.35b (down 3.0% from 1Q 2025). Net income: ₹74.5m (down 33% from 1Q 2025). Profit margin: 5.5% (down from 8.0% in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 6% per year.お知らせ • Jul 29Kopran Limited, Annual General Meeting, Sep 11, 2025Kopran Limited, Annual General Meeting, Sep 11, 2025, at 11:30 Indian Standard Time.お知らせ • Jul 18Kopran Limited to Report Q1, 2026 Results on Jul 29, 2025Kopran Limited announced that they will report Q1, 2026 results on Jul 29, 2025New Risk • Jun 23New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₹8.49b (US$97.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (₹8.49b market cap, or US$97.8m).Reported Earnings • May 16Full year 2025 earnings released: EPS: ₹7.99 (vs ₹10.57 in FY 2024)Full year 2025 results: EPS: ₹7.99 (down from ₹10.57 in FY 2024). Revenue: ₹6.31b (up 2.7% from FY 2024). Net income: ₹385.5m (down 24% from FY 2024). Profit margin: 6.1% (down from 8.3% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 7% per year.お知らせ • May 10Kopran Limited to Report Q4, 2025 Results on May 15, 2025Kopran Limited announced that they will report Q4, 2025 results on May 15, 2025Valuation Update With 7 Day Price Move • Apr 16Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹205, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total loss to shareholders of 24% over the past three years.お知らせ • Mar 22Kopran Limited (BSE:524280) agreed to acquire Kopran Laboratories Limited for INR 2.1 billion.Kopran Limited (BSE:524280) agreed to acquire Kopran Laboratories Limited for INR 2.1 billion on March 20, 2025. The consideration consists of 11.78 million common equity of Kopran Limited to be issued for common equity of Kopran Laboratories Limited. For the period ending December 31, 2024, Kopran Laboratories Limited reported total revenue of INR 696.06 million. As of December 31, 2024, Kopran Laboratories Limited reported total common equity of INR 725.93 million. The transaction is subject to approval of offer by acquirer shareholders and approval of offer by acquirer board. The deal has been approved by the board. Saffron Capital Advisors Private Limited acted as fairness opinion provider for Kopran Limited. Ernst & Young Merchant Banking Services Private Limited acted as fairness opinion provider for Kopran Limited. Armslength Advisors Private Limited acted as fairness opinion provider for Kopran Limited. Khandelwal Jain & Co acted as accountant for Kopran Laboratories Limited.Valuation Update With 7 Day Price Move • Mar 21Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹194, the stock trades at a trailing P/E ratio of 19.7x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total loss to shareholders of 33% over the past three years.Reported Earnings • Feb 12Third quarter 2025 earnings released: EPS: ₹2.16 (vs ₹3.28 in 3Q 2024)Third quarter 2025 results: EPS: ₹2.16 (down from ₹3.28 in 3Q 2024). Revenue: ₹1.66b (up 4.6% from 3Q 2024). Net income: ₹104.0m (down 34% from 3Q 2024). Profit margin: 6.3% (down from 9.9% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings.お知らせ • Feb 04Kopran Limited to Report Q3, 2025 Results on Feb 11, 2025Kopran Limited announced that they will report Q3, 2025 results on Feb 11, 2025New Risk • Feb 03New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₹8.69b (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.3% average weekly change). Market cap is less than US$100m (₹8.69b market cap, or US$99.8m).Reported Earnings • Nov 14Second quarter 2025 earnings released: EPS: ₹1.53 (vs ₹2.86 in 2Q 2024)Second quarter 2025 results: EPS: ₹1.53 (down from ₹2.86 in 2Q 2024). Revenue: ₹1.53b (flat on 2Q 2024). Net income: ₹73.8m (down 46% from 2Q 2024). Profit margin: 4.8% (down from 9.0% in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.Valuation Update With 7 Day Price Move • Nov 13Investor sentiment deteriorates as stock falls 25%After last week's 25% share price decline to ₹241, the stock trades at a trailing P/E ratio of 19.6x. Average trailing P/E is 36x in the Pharmaceuticals industry in India. Total returns to shareholders of 3.7% over the past three years.お知らせ • Nov 05Kopran Limited to Report Q2, 2025 Results on Nov 13, 2024Kopran Limited announced that they will report Q2, 2025 results on Nov 13, 2024Valuation Update With 7 Day Price Move • Sep 09Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹348, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 42x in the Pharmaceuticals industry in India. Total returns to shareholders of 71% over the past three years.Valuation Update With 7 Day Price Move • Aug 21Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹312, the stock trades at a trailing P/E ratio of 25.3x. Average trailing P/E is 37x in the Pharmaceuticals industry in India. Total returns to shareholders of 55% over the past three years.お知らせ • Aug 17Kopran Limited Recommends Dividend for the Financial Year Ended March 31, 2024The 65th Annual General Meeting of the members of Kopran Limited will be held on September 11, 2024, the Board of Directors has recommended a dividend of INR 3 (30%) per equity share of INR 10 for the Financial year ended March 31, 2024.Declared Dividend • Aug 16Dividend of ₹3.00 announcedDividend of ₹3.00 is the same as last year. Ex-date: 2nd September 2024 Payment date: 11th October 2024 Dividend yield will be 1.1%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (28% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has not increased over the past 4 years but payments have been stable during that time. Earnings per share has grown by 15% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.Reported Earnings • Aug 09First quarter 2025 earnings released: EPS: ₹2.30 (vs ₹0.58 in 1Q 2024)First quarter 2025 results: EPS: ₹2.30 (up from ₹0.58 in 1Q 2024). Revenue: ₹1.41b (up 20% from 1Q 2024). Net income: ₹111.0m (up 300% from 1Q 2024). Profit margin: 7.9% (up from 2.4% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.お知らせ • Jul 23Kopran Limited to Report Q1, 2025 Results on Aug 08, 2024Kopran Limited announced that they will report Q1, 2025 results on Aug 08, 2024Reported Earnings • May 18Full year 2024 earnings released: EPS: ₹10.57 (vs ₹5.65 in FY 2023)Full year 2024 results: EPS: ₹10.57 (up from ₹5.65 in FY 2023). Revenue: ₹6.22b (up 13% from FY 2023). Net income: ₹509.6m (up 87% from FY 2023). Profit margin: 8.2% (up from 4.9% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.お知らせ • May 18Kopran Limited, Annual General Meeting, Sep 11, 2024Kopran Limited, Annual General Meeting, Sep 11, 2024.お知らせ • May 17Kopran Limited Has Recommends Dividend for the Financial Year Ended March 31, 2024Kopran Limited has recommended dividend of INR 3.00 per Equity Share of F.V INR 10 (30%) for the financial year ended March 31, 2024. The dividend recommended by the Board is subject To Approve the Members of the Company at the forthcoming 65th Annual General Meeting, scheduled to be held on September 11, 2024.お知らせ • May 10Kopran Limited to Report Q4, 2024 Results on May 16, 2024Kopran Limited announced that they will report Q4, 2024 results on May 16, 2024Valuation Update With 7 Day Price Move • Mar 20Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹259, the stock trades at a trailing P/E ratio of 30.9x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 154% over the past three years.Reported Earnings • Feb 08Third quarter 2024 earnings released: EPS: ₹3.28 (vs ₹1.44 in 3Q 2023)Third quarter 2024 results: EPS: ₹3.28 (up from ₹1.44 in 3Q 2023). Revenue: ₹1.59b (flat on 3Q 2023). Net income: ₹157.9m (up 127% from 3Q 2023). Profit margin: 9.9% (up from 4.4% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings.お知らせ • Jan 23Kopran Limited to Report Q3, 2024 Results on Feb 07, 2024Kopran Limited announced that they will report Q3, 2024 results on Feb 07, 2024Valuation Update With 7 Day Price Move • Nov 20Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹274, the stock trades at a trailing P/E ratio of 41.8x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 140% over the past three years.Reported Earnings • Nov 08Second quarter 2024 earnings released: EPS: ₹2.86 (vs ₹0.97 in 2Q 2023)Second quarter 2024 results: EPS: ₹2.86 (up from ₹0.97 in 2Q 2023). Revenue: ₹1.53b (up 31% from 2Q 2023). Net income: ₹137.7m (up 196% from 2Q 2023). Profit margin: 9.0% (up from 4.0% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Oct 30Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹225, the stock trades at a trailing P/E ratio of 48.4x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 74% over the past three years.お知らせ • Oct 28Kopran Limited to Report Q2, 2024 Results on Nov 07, 2023Kopran Limited announced that they will report Q2, 2024 results on Nov 07, 2023Upcoming Dividend • Aug 31Upcoming dividend of ₹3.00 per share at 1.3% yieldEligible shareholders must have bought the stock before 07 September 2023. Payment date: 14 October 2023. Payout ratio is a comfortable 53% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Indian dividend payers (1.4%). Higher than average of industry peers (0.9%).New Risk • Aug 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (4.1% net profit margin).Valuation Update With 7 Day Price Move • Aug 24Investor sentiment improves as stock rises 37%After last week's 37% share price gain to ₹228, the stock trades at a trailing P/E ratio of 49x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 221% over the past three years.お知らせ • Aug 18Kopran Limited, Annual General Meeting, Sep 14, 2023Kopran Limited, Annual General Meeting, Sep 14, 2023. Agenda: To consider dividend.Reported Earnings • Aug 11First quarter 2024 earnings released: EPS: ₹0.58 (vs ₹1.58 in 1Q 2023)First quarter 2024 results: EPS: ₹0.58 (down from ₹1.58 in 1Q 2023). Revenue: ₹1.17b (down 6.8% from 1Q 2023). Net income: ₹27.7m (down 64% from 1Q 2023). Profit margin: 2.4% (down from 6.0% in 1Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 38% per year, which means it is well ahead of earnings.お知らせ • Aug 01Kopran Limited to Report Q1, 2024 Results on Aug 10, 2023Kopran Limited announced that they will report Q1, 2024 results on Aug 10, 2023Valuation Update With 7 Day Price Move • Jun 02Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₹179, the stock trades at a trailing P/E ratio of 31.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 537% over the past three years.Reported Earnings • May 26Full year 2023 earnings released: EPS: ₹5.65 (vs ₹13.77 in FY 2022)Full year 2023 results: EPS: ₹5.65 (down from ₹13.77 in FY 2022). Revenue: ₹5.54b (up 16% from FY 2022). Net income: ₹272.3m (down 55% from FY 2022). Profit margin: 4.9% (down from 13% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 72% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 26Kopran Limited Recommends Dividend for the Year Ended March 31, 2023Kopran Limited has recommended dividend of INR 3 per Equity Share of INR 10 (@ 30%) to the shareholders for the year ended March 31, 2023. The dividend recommended by the Board is subject to the approval of the shareholders at the upcoming 64th Annual General Meeting (AGM) of the Company subject to deduction of tax at source as applicable, on or before 30 days from the date of the Annual General Meeting.お知らせ • May 17Kopran Limited to Report Q4, 2023 Results on May 25, 2023Kopran Limited announced that they will report Q4, 2023 results at 12:15 PM, Indian Standard Time on May 25, 2023Recent Insider Transactions • Apr 05Executive Vice Chairman & MD recently bought ₹10m worth of stockOn the 31st of March, Surendra Somani bought around 94k shares on-market at roughly ₹107 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Surendra's only on-market trade for the last 12 months.Valuation Update With 7 Day Price Move • Feb 27Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹111, the stock trades at a trailing P/E ratio of 14.6x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 341% over the past three years.Reported Earnings • Feb 12Third quarter 2023 earnings released: EPS: ₹1.44 (vs ₹4.64 in 3Q 2022)Third quarter 2023 results: EPS: ₹1.44 (down from ₹4.64 in 3Q 2022). Revenue: ₹1.58b (up 20% from 3Q 2022). Net income: ₹69.5m (down 65% from 3Q 2022). Profit margin: 4.4% (down from 15% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 60% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jan 27Kopran Limited to Report Q3, 2023 Results on Feb 10, 2023Kopran Limited announced that they will report Q3, 2023 results at 12:15 PM, Indian Standard Time on Feb 10, 2023Valuation Update With 7 Day Price Move • Nov 28Investor sentiment improved over the past weekAfter last week's 24% share price gain to ₹169, the stock trades at a trailing P/E ratio of 16.3x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 431% over the past three years.Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: ₹0.97 (vs ₹3.95 in 2Q 2022)Second quarter 2023 results: EPS: ₹0.97 (down from ₹3.95 in 2Q 2022). Revenue: ₹1.17b (down 8.0% from 2Q 2022). Net income: ₹46.5m (down 73% from 2Q 2022). Profit margin: 4.0% (down from 13% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 3 highly experienced directors. Chairman Susheel Somani was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Nov 02Kopran Limited to Report Q2, 2023 Results on Nov 11, 2022Kopran Limited announced that they will report Q2, 2023 results on Nov 11, 2022Valuation Update With 7 Day Price Move • Oct 24Investor sentiment improved over the past weekAfter last week's 22% share price gain to ₹187, the stock trades at a trailing P/E ratio of 14.4x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 616% over the past three years.Reported Earnings • Aug 10Full year 2022 earnings releasedFull year 2022 results: Revenue: ₹4.78b (down 2.9% from FY 2021). Net income: ₹610.3m (flat on FY 2021). Profit margin: 13% (in line with FY 2021). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has increased by 85% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Aug 06Kopran Limited, Annual General Meeting, Aug 29, 2022Kopran Limited, Annual General Meeting, Aug 29, 2022, at 11:30 Indian Standard Time. Agenda: To consider adoption of the Annual Audited Financial Statement & Reports thereon; to consider adoption of the Audited Consolidated Financial Statements; to declare Final dividend on Equity Shares; To consider appointment of a Director in place of one retiring by rotation; to consider re-appointment of Statutory Auditor; and to consider re-appointment of Mr. Surendra Somani as the Executive Vice Chairman of the Company.お知らせ • Aug 03Kopran Limited to Report Q1, 2023 Results on Aug 10, 2022Kopran Limited announced that they will report Q1, 2023 results on Aug 10, 2022Upcoming Dividend • Jul 28Upcoming dividend of ₹3.00 per shareEligible shareholders must have bought the stock before 04 August 2022. Payment date: 28 September 2022. Payout ratio is a comfortable 22% but the company is not cash flow positive. Trailing yield: 1.5%. Lower than top quartile of Indian dividend payers (1.8%). Higher than average of industry peers (1.0%).Valuation Update With 7 Day Price Move • Jun 20Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹183, the stock trades at a trailing P/E ratio of 14.4x. Average trailing P/E is 20x in the Pharmaceuticals industry in India. Total returns to shareholders of 447% over the past three years.Board Change • Jun 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Chairman Susheel Somani was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • May 29Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: ₹13.77 (down from ₹14.24 in FY 2021). Revenue: ₹4.81b (down 2.3% from FY 2021). Net income: ₹610.3m (flat on FY 2021). Profit margin: 13% (in line with FY 2021). Revenue missed analyst estimates by 3.0%. Earnings per share (EPS) also missed analyst estimates by 13%. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has increased by 77% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 28Kopran Limited Recommends Dividend for the Financial Year 2021-2022The board of directors of Kopran Limited meeting held on May 27, 2022, recommended dividend of INR 3.00 per equity Share of F.V INR 10 (30%) to the Members of the Company for declaration at the forthcoming 63rd Annual General Meeting for the Financial Year 2021-2022.お知らせ • May 15Kopran Limited to Report Q4, 2022 Results on May 27, 2022Kopran Limited announced that they will report Q4, 2022 results on May 27, 2022Valuation Update With 7 Day Price Move • May 10Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹220, the stock trades at a trailing P/E ratio of 19.1x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 493% over the past three years.Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹252, the stock trades at a trailing P/E ratio of 20.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 600% over the past three years.Reported Earnings • Feb 04Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: EPS: ₹4.64 (up from ₹3.63 in 3Q 2021). Revenue: ₹1.32b (up 18% from 3Q 2021). Net income: ₹200.7m (up 28% from 3Q 2021). Profit margin: 15% (up from 14% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 3.0%. Earnings per share (EPS) also missed analyst estimates by 13%. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has increased by 98% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Dec 28Investor sentiment improved over the past weekAfter last week's 24% share price gain to ₹352, the stock trades at a trailing P/E ratio of 28.1x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 821% over the past three years.お知らせ • Dec 09Kopran Limited announced that it expects to receive INR 1.264799745 billion in funding from Mahima Stocks Pvt Ltd, MC Jain Infoservices Private Limited, United Shippers Limited, Oricon Enterprises Limited and other investorsKopran Limited announced a private placement of up to 4,959,999 common shares of face value of INR 10 per share at an issue price of INR 255 per share including a premium of INR 245 per share for gross proceeds of INR 1,264,799,745 on December 8, 2021. The transaction will include participation from Mahima Stocks Pvt Ltd for 500,000 shares, MC Jain Infoservices Private Limited for 200,000 shares, promoter group United Shippers Limited for 2,200,000 shares and returning investor Oricon Enterprises Limited for 200,000 shares and 8 individual investors including Vivek Mundra for 100,000 shares. The company will issue securities on a preferential basis. The transaction has been approved in the Meeting of the Board of Directors of the company and is subject to the approval of regulatory/statutory authorities and the shareholders of the company at the forthcoming Extraordinary General Meeting.Reported Earnings • Oct 29Second quarter 2022 earnings released: EPS ₹3.95 (vs ₹3.84 in 2Q 2021)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2022 results: Revenue: ₹1.28b (up 7.6% from 2Q 2021). Net income: ₹170.9m (up 2.8% from 2Q 2021). Profit margin: 13% (in line with 2Q 2021). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 72% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Aug 12First quarter 2022 earnings released: EPS ₹1.47 (vs ₹3.29 in 1Q 2021)The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹753.3m (down 38% from 1Q 2021). Net income: ₹63.6m (down 55% from 1Q 2021). Profit margin: 8.4% (down from 12% in 1Q 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 64% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Aug 04Full year 2021 earnings released: EPS ₹14.24 (vs ₹4.86 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹4.92b (up 37% from FY 2020). Net income: ₹616.1m (up 193% from FY 2020). Profit margin: 13% (up from 5.8% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has increased by 64% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Jul 29Upcoming dividend of ₹1.50 per shareEligible shareholders must have bought the stock before 05 August 2021. Payment date: 30 September 2021. Trailing yield: 1.2%. Lower than top quartile of Indian dividend payers (1.4%). Higher than average of industry peers (0.8%).Valuation Update With 7 Day Price Move • Jul 01Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹232, the stock trades at a trailing P/E ratio of 16.3x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 332% over the past three years.Reported Earnings • May 30Full year 2021 earnings released: EPS ₹14.24 (vs ₹4.86 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹4.94b (up 37% from FY 2020). Net income: ₹616.1m (up 193% from FY 2020). Profit margin: 13% (up from 5.8% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 28Kopran Limited Recommends Final Dividend for the Year Ended 31 March 2021The Board of Kopran Limited has recommended a Final dividend of INR 1.50 (15%) per equity share of INR 10 each for the year ended 31st March 2021 subject to approval of members at the 62nd AGM. Earlier an interim dividend of INR 1.50 (15%) per equity share was paid in the month of November, 2020.Valuation Update With 7 Day Price Move • May 11Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₹227, the stock trades at a trailing P/E ratio of 19.1x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 263% over the past three years.Valuation Update With 7 Day Price Move • Apr 21Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹136, the stock trades at a trailing P/E ratio of 11.5x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 101% over the past three years.Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹119, the stock trades at a trailing P/E ratio of 10x. Average trailing P/E is 18x in the Pharmaceuticals industry in India. Total returns to shareholders of 90% over the past three years.Is New 90 Day High Low • Mar 12New 90-day low: ₹111The company is down 16% from its price of ₹133 on 11 December 2020. The Indian market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period.Is New 90 Day High Low • Jan 27New 90-day low: ₹113The company is down 9.0% from its price of ₹124 on 29 October 2020. The Indian market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period.Reported Earnings • Jan 23Third quarter 2021 earnings released: EPS ₹3.63The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹1.12b (up 12% from 3Q 2020). Net income: ₹157.1m (up 149% from 3Q 2020). Profit margin: 14% (up from 6.3% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.株主還元524280IN PharmaceuticalsIN 市場7D3.6%3.3%1.0%1Y6.7%12.6%-1.4%株主還元を見る業界別リターン: 524280過去 1 年間で12.6 % の収益を上げたIndian Pharmaceuticals業界を下回りました。リターン対市場: 524280過去 1 年間で-1.4 % の収益を上げたIndian市場を上回りました。価格変動Is 524280's price volatile compared to industry and market?524280 volatility524280 Average Weekly Movement8.6%Pharmaceuticals Industry Average Movement6.6%Market Average Movement6.4%10% most volatile stocks in IN Market9.3%10% least volatile stocks in IN Market4.1%安定した株価: 524280の株価は、 Indian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 524280の weekly volatility ( 9% ) は過去 1 年間安定していますが、依然としてIndianの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19581,024Surendra Somaniwww.kopran.com総合製薬企業であるコプラン・リミテッドは、インド国内外において医薬品原薬および最終製剤の製造・販売を行っている。同社は、錠剤、カプセル剤、シロップ剤、ドライパウダー、懸濁剤、注射剤などの様々な剤形や、ブランド製剤、ジェネリック製剤で製品を提供している。また、マクロライド系、抗菌薬、抗けいれん薬、降圧薬、抗炎症薬、抗ニキビ薬、抗感染症薬、抗血栓薬、抗糖尿病薬、疼痛管理薬、神経調節薬、消化器官用薬、循環器官用薬などのカテゴリーで医薬品を提供している。さらに、勃起不全、抗アレルギー、呼吸器、腫瘍、中枢神経、抗原虫、駆虫薬、抗消化性潰瘍・腸、その他の医薬品も提供している。コプラン社は1958年に設立され、インドのムンバイに本社を置いている。もっと見るKopran Limited 基礎のまとめKopran の収益と売上を時価総額と比較するとどうか。524280 基礎統計学時価総額₹9.31b収益（TTM）₹257.31m売上高(TTM)₹6.81b36.2xPER（株価収益率1.4xP/Sレシオ524280 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計524280 損益計算書（TTM）収益₹6.81b売上原価₹4.39b売上総利益₹2.42bその他の費用₹2.17b収益₹257.31m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）5.33グロス・マージン35.57%純利益率3.78%有利子負債／自己資本比率28.8%524280 の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.6%現在の配当利回り56%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/06 00:27終値2026/07/06 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Kopran Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Rohit Bhat360 ONE Capital Market Private LimitedHarini V.FirstCall Research
New Risk • May 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (9.3% average weekly change). Profit margins are more than 30% lower than last year (3.8% net profit margin). Market cap is less than US$100m (₹9.11b market cap, or US$95.6m).
New Risk • May 21New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.8% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (3.8% net profit margin). Market cap is less than US$100m (₹8.07b market cap, or US$83.9m).
Reported Earnings • May 21Full year 2026 earnings released: EPS: ₹5.33 (vs ₹7.98 in FY 2025)Full year 2026 results: EPS: ₹5.33 (down from ₹7.98 in FY 2025). Revenue: ₹6.82b (up 8.3% from FY 2025). Net income: ₹257.3m (down 33% from FY 2025). Profit margin: 3.8% (down from 6.1% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • May 19Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹172, the stock trades at a trailing P/E ratio of 50.3x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 22% over the past three years.
お知らせ • May 06Kopran Limited to Report Q4, 2026 Results on May 19, 2026Kopran Limited announced that they will report Q4, 2026 results on May 19, 2026
Buy Or Sell Opportunity • Apr 08Now 21% overvaluedOver the last 90 days, the stock has fallen 3.8% to ₹146. The fair value is estimated to be ₹121, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.8% over the last 3 years. Earnings per share has declined by 5.0%.
New Risk • May 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (9.3% average weekly change). Profit margins are more than 30% lower than last year (3.8% net profit margin). Market cap is less than US$100m (₹9.11b market cap, or US$95.6m).
New Risk • May 21New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.8% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (3.8% net profit margin). Market cap is less than US$100m (₹8.07b market cap, or US$83.9m).
Reported Earnings • May 21Full year 2026 earnings released: EPS: ₹5.33 (vs ₹7.98 in FY 2025)Full year 2026 results: EPS: ₹5.33 (down from ₹7.98 in FY 2025). Revenue: ₹6.82b (up 8.3% from FY 2025). Net income: ₹257.3m (down 33% from FY 2025). Profit margin: 3.8% (down from 6.1% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • May 19Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹172, the stock trades at a trailing P/E ratio of 50.3x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 22% over the past three years.
お知らせ • May 06Kopran Limited to Report Q4, 2026 Results on May 19, 2026Kopran Limited announced that they will report Q4, 2026 results on May 19, 2026
Buy Or Sell Opportunity • Apr 08Now 21% overvaluedOver the last 90 days, the stock has fallen 3.8% to ₹146. The fair value is estimated to be ₹121, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.8% over the last 3 years. Earnings per share has declined by 5.0%.
Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹125, the stock trades at a trailing P/E ratio of 36.6x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 3.8% over the past three years.
Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹142, the stock trades at a trailing P/E ratio of 41.4x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 16% over the past three years.
Buy Or Sell Opportunity • Feb 04Now 22% overvaluedOver the last 90 days, the stock has fallen 14% to ₹138. The fair value is estimated to be ₹113, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.8% over the last 3 years. Earnings per share has declined by 5.0%.
New Risk • Feb 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Profit margins are more than 30% lower than last year (2.7% net profit margin). Market cap is less than US$100m (₹6.48b market cap, or US$71.8m).
Reported Earnings • Jan 24Third quarter 2026 earnings released: EPS: ₹1.93 (vs ₹2.16 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.93 (down from ₹2.16 in 3Q 2025). Revenue: ₹1.94b (up 17% from 3Q 2025). Net income: ₹93.4m (down 10% from 3Q 2025). Profit margin: 4.8% (down from 6.3% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 1% per year.
お知らせ • Jan 13Kopran Limited to Report Q3, 2026 Results on Jan 22, 2026Kopran Limited announced that they will report Q3, 2026 results on Jan 22, 2026
Valuation Update With 7 Day Price Move • Dec 23Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹153, the stock trades at a trailing P/E ratio of 42x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 3.0% over the past three years.
Reported Earnings • Nov 17Second quarter 2026 earnings released: ₹2.06 loss per share (vs ₹1.53 profit in 2Q 2025)Second quarter 2026 results: ₹2.06 loss per share (down from ₹1.53 profit in 2Q 2025). Revenue: ₹1.18b (down 22% from 2Q 2025). Net loss: ₹99.2m (down 234% from profit in 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has increased by 1% per year.
お知らせ • Oct 31Kopran Limited to Report Q2, 2026 Results on Nov 12, 2025Kopran Limited announced that they will report Q2, 2026 results on Nov 12, 2025
お知らせ • Sep 11Kopran Limited Appoints Chandresh Gunvant Gandhi as Independent DirectorKopran Limited at its Sixty-sixth Annual General Meeting held on September 11, 2025, approved the appointment of Mr. Chandresh Gunvant Gandhi (DIN: 00707947) as an Independent Director.
Valuation Update With 7 Day Price Move • Sep 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹185, the stock trades at a trailing P/E ratio of 25.5x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 8.8% over the past three years.
Upcoming Dividend • Aug 28Upcoming dividend of ₹3.00 per shareEligible shareholders must have bought the stock before 04 September 2025. Payment date: 11 October 2025. Payout ratio is a comfortable 38% but the company is not cash flow positive. Trailing yield: 1.9%. Within top quartile of Indian dividend payers (1.3%). Higher than average of industry peers (0.8%).
Declared Dividend • Aug 13Dividend of ₹3.00 announcedDividend of ₹3.00 is the same as last year. Ex-date: 4th September 2025 Payment date: 11th October 2025 Dividend yield will be 1.9%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (38% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has not increased over the past 5 years but payments have been stable during that time. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend.
New Risk • Jul 30New major risk - Revenue and earnings growthEarnings have declined by 3.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.7% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (5.6% net profit margin). Market cap is less than US$100m (₹8.13b market cap, or US$93.1m).
Reported Earnings • Jul 30First quarter 2026 earnings released: EPS: ₹1.54 (vs ₹2.30 in 1Q 2025)First quarter 2026 results: EPS: ₹1.54 (down from ₹2.30 in 1Q 2025). Revenue: ₹1.35b (down 3.0% from 1Q 2025). Net income: ₹74.5m (down 33% from 1Q 2025). Profit margin: 5.5% (down from 8.0% in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 6% per year.
お知らせ • Jul 29Kopran Limited, Annual General Meeting, Sep 11, 2025Kopran Limited, Annual General Meeting, Sep 11, 2025, at 11:30 Indian Standard Time.
お知らせ • Jul 18Kopran Limited to Report Q1, 2026 Results on Jul 29, 2025Kopran Limited announced that they will report Q1, 2026 results on Jul 29, 2025
New Risk • Jun 23New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₹8.49b (US$97.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (₹8.49b market cap, or US$97.8m).
Reported Earnings • May 16Full year 2025 earnings released: EPS: ₹7.99 (vs ₹10.57 in FY 2024)Full year 2025 results: EPS: ₹7.99 (down from ₹10.57 in FY 2024). Revenue: ₹6.31b (up 2.7% from FY 2024). Net income: ₹385.5m (down 24% from FY 2024). Profit margin: 6.1% (down from 8.3% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 7% per year.
お知らせ • May 10Kopran Limited to Report Q4, 2025 Results on May 15, 2025Kopran Limited announced that they will report Q4, 2025 results on May 15, 2025
Valuation Update With 7 Day Price Move • Apr 16Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹205, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total loss to shareholders of 24% over the past three years.
お知らせ • Mar 22Kopran Limited (BSE:524280) agreed to acquire Kopran Laboratories Limited for INR 2.1 billion.Kopran Limited (BSE:524280) agreed to acquire Kopran Laboratories Limited for INR 2.1 billion on March 20, 2025. The consideration consists of 11.78 million common equity of Kopran Limited to be issued for common equity of Kopran Laboratories Limited. For the period ending December 31, 2024, Kopran Laboratories Limited reported total revenue of INR 696.06 million. As of December 31, 2024, Kopran Laboratories Limited reported total common equity of INR 725.93 million. The transaction is subject to approval of offer by acquirer shareholders and approval of offer by acquirer board. The deal has been approved by the board. Saffron Capital Advisors Private Limited acted as fairness opinion provider for Kopran Limited. Ernst & Young Merchant Banking Services Private Limited acted as fairness opinion provider for Kopran Limited. Armslength Advisors Private Limited acted as fairness opinion provider for Kopran Limited. Khandelwal Jain & Co acted as accountant for Kopran Laboratories Limited.
Valuation Update With 7 Day Price Move • Mar 21Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹194, the stock trades at a trailing P/E ratio of 19.7x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total loss to shareholders of 33% over the past three years.
Reported Earnings • Feb 12Third quarter 2025 earnings released: EPS: ₹2.16 (vs ₹3.28 in 3Q 2024)Third quarter 2025 results: EPS: ₹2.16 (down from ₹3.28 in 3Q 2024). Revenue: ₹1.66b (up 4.6% from 3Q 2024). Net income: ₹104.0m (down 34% from 3Q 2024). Profit margin: 6.3% (down from 9.9% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings.
お知らせ • Feb 04Kopran Limited to Report Q3, 2025 Results on Feb 11, 2025Kopran Limited announced that they will report Q3, 2025 results on Feb 11, 2025
New Risk • Feb 03New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₹8.69b (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.3% average weekly change). Market cap is less than US$100m (₹8.69b market cap, or US$99.8m).
Reported Earnings • Nov 14Second quarter 2025 earnings released: EPS: ₹1.53 (vs ₹2.86 in 2Q 2024)Second quarter 2025 results: EPS: ₹1.53 (down from ₹2.86 in 2Q 2024). Revenue: ₹1.53b (flat on 2Q 2024). Net income: ₹73.8m (down 46% from 2Q 2024). Profit margin: 4.8% (down from 9.0% in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
Valuation Update With 7 Day Price Move • Nov 13Investor sentiment deteriorates as stock falls 25%After last week's 25% share price decline to ₹241, the stock trades at a trailing P/E ratio of 19.6x. Average trailing P/E is 36x in the Pharmaceuticals industry in India. Total returns to shareholders of 3.7% over the past three years.
お知らせ • Nov 05Kopran Limited to Report Q2, 2025 Results on Nov 13, 2024Kopran Limited announced that they will report Q2, 2025 results on Nov 13, 2024
Valuation Update With 7 Day Price Move • Sep 09Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹348, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 42x in the Pharmaceuticals industry in India. Total returns to shareholders of 71% over the past three years.
Valuation Update With 7 Day Price Move • Aug 21Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹312, the stock trades at a trailing P/E ratio of 25.3x. Average trailing P/E is 37x in the Pharmaceuticals industry in India. Total returns to shareholders of 55% over the past three years.
お知らせ • Aug 17Kopran Limited Recommends Dividend for the Financial Year Ended March 31, 2024The 65th Annual General Meeting of the members of Kopran Limited will be held on September 11, 2024, the Board of Directors has recommended a dividend of INR 3 (30%) per equity share of INR 10 for the Financial year ended March 31, 2024.
Declared Dividend • Aug 16Dividend of ₹3.00 announcedDividend of ₹3.00 is the same as last year. Ex-date: 2nd September 2024 Payment date: 11th October 2024 Dividend yield will be 1.1%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (28% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has not increased over the past 4 years but payments have been stable during that time. Earnings per share has grown by 15% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
Reported Earnings • Aug 09First quarter 2025 earnings released: EPS: ₹2.30 (vs ₹0.58 in 1Q 2024)First quarter 2025 results: EPS: ₹2.30 (up from ₹0.58 in 1Q 2024). Revenue: ₹1.41b (up 20% from 1Q 2024). Net income: ₹111.0m (up 300% from 1Q 2024). Profit margin: 7.9% (up from 2.4% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
お知らせ • Jul 23Kopran Limited to Report Q1, 2025 Results on Aug 08, 2024Kopran Limited announced that they will report Q1, 2025 results on Aug 08, 2024
Reported Earnings • May 18Full year 2024 earnings released: EPS: ₹10.57 (vs ₹5.65 in FY 2023)Full year 2024 results: EPS: ₹10.57 (up from ₹5.65 in FY 2023). Revenue: ₹6.22b (up 13% from FY 2023). Net income: ₹509.6m (up 87% from FY 2023). Profit margin: 8.2% (up from 4.9% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
お知らせ • May 18Kopran Limited, Annual General Meeting, Sep 11, 2024Kopran Limited, Annual General Meeting, Sep 11, 2024.
お知らせ • May 17Kopran Limited Has Recommends Dividend for the Financial Year Ended March 31, 2024Kopran Limited has recommended dividend of INR 3.00 per Equity Share of F.V INR 10 (30%) for the financial year ended March 31, 2024. The dividend recommended by the Board is subject To Approve the Members of the Company at the forthcoming 65th Annual General Meeting, scheduled to be held on September 11, 2024.
お知らせ • May 10Kopran Limited to Report Q4, 2024 Results on May 16, 2024Kopran Limited announced that they will report Q4, 2024 results on May 16, 2024
Valuation Update With 7 Day Price Move • Mar 20Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹259, the stock trades at a trailing P/E ratio of 30.9x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 154% over the past three years.
Reported Earnings • Feb 08Third quarter 2024 earnings released: EPS: ₹3.28 (vs ₹1.44 in 3Q 2023)Third quarter 2024 results: EPS: ₹3.28 (up from ₹1.44 in 3Q 2023). Revenue: ₹1.59b (flat on 3Q 2023). Net income: ₹157.9m (up 127% from 3Q 2023). Profit margin: 9.9% (up from 4.4% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings.
お知らせ • Jan 23Kopran Limited to Report Q3, 2024 Results on Feb 07, 2024Kopran Limited announced that they will report Q3, 2024 results on Feb 07, 2024
Valuation Update With 7 Day Price Move • Nov 20Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹274, the stock trades at a trailing P/E ratio of 41.8x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 140% over the past three years.
Reported Earnings • Nov 08Second quarter 2024 earnings released: EPS: ₹2.86 (vs ₹0.97 in 2Q 2023)Second quarter 2024 results: EPS: ₹2.86 (up from ₹0.97 in 2Q 2023). Revenue: ₹1.53b (up 31% from 2Q 2023). Net income: ₹137.7m (up 196% from 2Q 2023). Profit margin: 9.0% (up from 4.0% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Oct 30Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹225, the stock trades at a trailing P/E ratio of 48.4x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 74% over the past three years.
お知らせ • Oct 28Kopran Limited to Report Q2, 2024 Results on Nov 07, 2023Kopran Limited announced that they will report Q2, 2024 results on Nov 07, 2023
Upcoming Dividend • Aug 31Upcoming dividend of ₹3.00 per share at 1.3% yieldEligible shareholders must have bought the stock before 07 September 2023. Payment date: 14 October 2023. Payout ratio is a comfortable 53% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Indian dividend payers (1.4%). Higher than average of industry peers (0.9%).
New Risk • Aug 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (4.1% net profit margin).
Valuation Update With 7 Day Price Move • Aug 24Investor sentiment improves as stock rises 37%After last week's 37% share price gain to ₹228, the stock trades at a trailing P/E ratio of 49x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 221% over the past three years.
お知らせ • Aug 18Kopran Limited, Annual General Meeting, Sep 14, 2023Kopran Limited, Annual General Meeting, Sep 14, 2023. Agenda: To consider dividend.
Reported Earnings • Aug 11First quarter 2024 earnings released: EPS: ₹0.58 (vs ₹1.58 in 1Q 2023)First quarter 2024 results: EPS: ₹0.58 (down from ₹1.58 in 1Q 2023). Revenue: ₹1.17b (down 6.8% from 1Q 2023). Net income: ₹27.7m (down 64% from 1Q 2023). Profit margin: 2.4% (down from 6.0% in 1Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 38% per year, which means it is well ahead of earnings.
お知らせ • Aug 01Kopran Limited to Report Q1, 2024 Results on Aug 10, 2023Kopran Limited announced that they will report Q1, 2024 results on Aug 10, 2023
Valuation Update With 7 Day Price Move • Jun 02Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₹179, the stock trades at a trailing P/E ratio of 31.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 537% over the past three years.
Reported Earnings • May 26Full year 2023 earnings released: EPS: ₹5.65 (vs ₹13.77 in FY 2022)Full year 2023 results: EPS: ₹5.65 (down from ₹13.77 in FY 2022). Revenue: ₹5.54b (up 16% from FY 2022). Net income: ₹272.3m (down 55% from FY 2022). Profit margin: 4.9% (down from 13% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 72% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 26Kopran Limited Recommends Dividend for the Year Ended March 31, 2023Kopran Limited has recommended dividend of INR 3 per Equity Share of INR 10 (@ 30%) to the shareholders for the year ended March 31, 2023. The dividend recommended by the Board is subject to the approval of the shareholders at the upcoming 64th Annual General Meeting (AGM) of the Company subject to deduction of tax at source as applicable, on or before 30 days from the date of the Annual General Meeting.
お知らせ • May 17Kopran Limited to Report Q4, 2023 Results on May 25, 2023Kopran Limited announced that they will report Q4, 2023 results at 12:15 PM, Indian Standard Time on May 25, 2023
Recent Insider Transactions • Apr 05Executive Vice Chairman & MD recently bought ₹10m worth of stockOn the 31st of March, Surendra Somani bought around 94k shares on-market at roughly ₹107 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Surendra's only on-market trade for the last 12 months.
Valuation Update With 7 Day Price Move • Feb 27Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹111, the stock trades at a trailing P/E ratio of 14.6x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 341% over the past three years.
Reported Earnings • Feb 12Third quarter 2023 earnings released: EPS: ₹1.44 (vs ₹4.64 in 3Q 2022)Third quarter 2023 results: EPS: ₹1.44 (down from ₹4.64 in 3Q 2022). Revenue: ₹1.58b (up 20% from 3Q 2022). Net income: ₹69.5m (down 65% from 3Q 2022). Profit margin: 4.4% (down from 15% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 60% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jan 27Kopran Limited to Report Q3, 2023 Results on Feb 10, 2023Kopran Limited announced that they will report Q3, 2023 results at 12:15 PM, Indian Standard Time on Feb 10, 2023
Valuation Update With 7 Day Price Move • Nov 28Investor sentiment improved over the past weekAfter last week's 24% share price gain to ₹169, the stock trades at a trailing P/E ratio of 16.3x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 431% over the past three years.
Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: ₹0.97 (vs ₹3.95 in 2Q 2022)Second quarter 2023 results: EPS: ₹0.97 (down from ₹3.95 in 2Q 2022). Revenue: ₹1.17b (down 8.0% from 2Q 2022). Net income: ₹46.5m (down 73% from 2Q 2022). Profit margin: 4.0% (down from 13% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 3 highly experienced directors. Chairman Susheel Somani was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 02Kopran Limited to Report Q2, 2023 Results on Nov 11, 2022Kopran Limited announced that they will report Q2, 2023 results on Nov 11, 2022
Valuation Update With 7 Day Price Move • Oct 24Investor sentiment improved over the past weekAfter last week's 22% share price gain to ₹187, the stock trades at a trailing P/E ratio of 14.4x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 616% over the past three years.
Reported Earnings • Aug 10Full year 2022 earnings releasedFull year 2022 results: Revenue: ₹4.78b (down 2.9% from FY 2021). Net income: ₹610.3m (flat on FY 2021). Profit margin: 13% (in line with FY 2021). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has increased by 85% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Aug 06Kopran Limited, Annual General Meeting, Aug 29, 2022Kopran Limited, Annual General Meeting, Aug 29, 2022, at 11:30 Indian Standard Time. Agenda: To consider adoption of the Annual Audited Financial Statement & Reports thereon; to consider adoption of the Audited Consolidated Financial Statements; to declare Final dividend on Equity Shares; To consider appointment of a Director in place of one retiring by rotation; to consider re-appointment of Statutory Auditor; and to consider re-appointment of Mr. Surendra Somani as the Executive Vice Chairman of the Company.
お知らせ • Aug 03Kopran Limited to Report Q1, 2023 Results on Aug 10, 2022Kopran Limited announced that they will report Q1, 2023 results on Aug 10, 2022
Upcoming Dividend • Jul 28Upcoming dividend of ₹3.00 per shareEligible shareholders must have bought the stock before 04 August 2022. Payment date: 28 September 2022. Payout ratio is a comfortable 22% but the company is not cash flow positive. Trailing yield: 1.5%. Lower than top quartile of Indian dividend payers (1.8%). Higher than average of industry peers (1.0%).
Valuation Update With 7 Day Price Move • Jun 20Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹183, the stock trades at a trailing P/E ratio of 14.4x. Average trailing P/E is 20x in the Pharmaceuticals industry in India. Total returns to shareholders of 447% over the past three years.
Board Change • Jun 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Chairman Susheel Somani was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • May 29Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: ₹13.77 (down from ₹14.24 in FY 2021). Revenue: ₹4.81b (down 2.3% from FY 2021). Net income: ₹610.3m (flat on FY 2021). Profit margin: 13% (in line with FY 2021). Revenue missed analyst estimates by 3.0%. Earnings per share (EPS) also missed analyst estimates by 13%. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has increased by 77% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 28Kopran Limited Recommends Dividend for the Financial Year 2021-2022The board of directors of Kopran Limited meeting held on May 27, 2022, recommended dividend of INR 3.00 per equity Share of F.V INR 10 (30%) to the Members of the Company for declaration at the forthcoming 63rd Annual General Meeting for the Financial Year 2021-2022.
お知らせ • May 15Kopran Limited to Report Q4, 2022 Results on May 27, 2022Kopran Limited announced that they will report Q4, 2022 results on May 27, 2022
Valuation Update With 7 Day Price Move • May 10Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹220, the stock trades at a trailing P/E ratio of 19.1x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 493% over the past three years.
Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹252, the stock trades at a trailing P/E ratio of 20.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 600% over the past three years.
Reported Earnings • Feb 04Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: EPS: ₹4.64 (up from ₹3.63 in 3Q 2021). Revenue: ₹1.32b (up 18% from 3Q 2021). Net income: ₹200.7m (up 28% from 3Q 2021). Profit margin: 15% (up from 14% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 3.0%. Earnings per share (EPS) also missed analyst estimates by 13%. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has increased by 98% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Dec 28Investor sentiment improved over the past weekAfter last week's 24% share price gain to ₹352, the stock trades at a trailing P/E ratio of 28.1x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 821% over the past three years.
お知らせ • Dec 09Kopran Limited announced that it expects to receive INR 1.264799745 billion in funding from Mahima Stocks Pvt Ltd, MC Jain Infoservices Private Limited, United Shippers Limited, Oricon Enterprises Limited and other investorsKopran Limited announced a private placement of up to 4,959,999 common shares of face value of INR 10 per share at an issue price of INR 255 per share including a premium of INR 245 per share for gross proceeds of INR 1,264,799,745 on December 8, 2021. The transaction will include participation from Mahima Stocks Pvt Ltd for 500,000 shares, MC Jain Infoservices Private Limited for 200,000 shares, promoter group United Shippers Limited for 2,200,000 shares and returning investor Oricon Enterprises Limited for 200,000 shares and 8 individual investors including Vivek Mundra for 100,000 shares. The company will issue securities on a preferential basis. The transaction has been approved in the Meeting of the Board of Directors of the company and is subject to the approval of regulatory/statutory authorities and the shareholders of the company at the forthcoming Extraordinary General Meeting.
Reported Earnings • Oct 29Second quarter 2022 earnings released: EPS ₹3.95 (vs ₹3.84 in 2Q 2021)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2022 results: Revenue: ₹1.28b (up 7.6% from 2Q 2021). Net income: ₹170.9m (up 2.8% from 2Q 2021). Profit margin: 13% (in line with 2Q 2021). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 72% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Aug 12First quarter 2022 earnings released: EPS ₹1.47 (vs ₹3.29 in 1Q 2021)The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹753.3m (down 38% from 1Q 2021). Net income: ₹63.6m (down 55% from 1Q 2021). Profit margin: 8.4% (down from 12% in 1Q 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 64% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Aug 04Full year 2021 earnings released: EPS ₹14.24 (vs ₹4.86 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹4.92b (up 37% from FY 2020). Net income: ₹616.1m (up 193% from FY 2020). Profit margin: 13% (up from 5.8% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has increased by 64% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Jul 29Upcoming dividend of ₹1.50 per shareEligible shareholders must have bought the stock before 05 August 2021. Payment date: 30 September 2021. Trailing yield: 1.2%. Lower than top quartile of Indian dividend payers (1.4%). Higher than average of industry peers (0.8%).
Valuation Update With 7 Day Price Move • Jul 01Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹232, the stock trades at a trailing P/E ratio of 16.3x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 332% over the past three years.
Reported Earnings • May 30Full year 2021 earnings released: EPS ₹14.24 (vs ₹4.86 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹4.94b (up 37% from FY 2020). Net income: ₹616.1m (up 193% from FY 2020). Profit margin: 13% (up from 5.8% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 28Kopran Limited Recommends Final Dividend for the Year Ended 31 March 2021The Board of Kopran Limited has recommended a Final dividend of INR 1.50 (15%) per equity share of INR 10 each for the year ended 31st March 2021 subject to approval of members at the 62nd AGM. Earlier an interim dividend of INR 1.50 (15%) per equity share was paid in the month of November, 2020.
Valuation Update With 7 Day Price Move • May 11Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₹227, the stock trades at a trailing P/E ratio of 19.1x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 263% over the past three years.
Valuation Update With 7 Day Price Move • Apr 21Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹136, the stock trades at a trailing P/E ratio of 11.5x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 101% over the past three years.
Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹119, the stock trades at a trailing P/E ratio of 10x. Average trailing P/E is 18x in the Pharmaceuticals industry in India. Total returns to shareholders of 90% over the past three years.
Is New 90 Day High Low • Mar 12New 90-day low: ₹111The company is down 16% from its price of ₹133 on 11 December 2020. The Indian market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period.
Is New 90 Day High Low • Jan 27New 90-day low: ₹113The company is down 9.0% from its price of ₹124 on 29 October 2020. The Indian market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period.
Reported Earnings • Jan 23Third quarter 2021 earnings released: EPS ₹3.63The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹1.12b (up 12% from 3Q 2020). Net income: ₹157.1m (up 149% from 3Q 2020). Profit margin: 14% (up from 6.3% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.
